{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00025968", "CSN": null, "TRF": "ORD_1537951_01", "MRN": "41872371", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1258158", "clinicalId": "1259528", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1537951_01", "SampleName": "US1470939.01", "Version": "0", "Sample": {"FM_Id": "ORD_1537951_01", "SampleId": "US1470939.01", "BlockId": "S111-68476K ", "TRFNumber": "ORD_1537951_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_01_05", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10011", "MRN": "41872371", "FullName": "\u97d3\u4f0a\u8299", "FirstName": "I Fu", "LastName": "Han", "SubmittedDiagnosis": "Ovarian clear cell carcinoma", "Gender": "Female", "DOB": "1985_02_07", "OrderingMD": "\u9673\u6021\u4ec1", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u582f", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Ovary", "CollDate": "2022_09_28", "ReceivedDate": "2023-01-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Ovarian Cancer"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRCA1"}, {"Gene": "BRCA2"}]}, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "20", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ARID1A", "isVUS": "true", "variantName": "Q1334_R1335insQ"}, {"geneName": "CDKN2A/B", "isVUS": "true", "variantName": "R109H"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "P627S"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "I698T"}, {"geneName": "FANCA", "isVUS": "true", "variantName": "S645F"}, {"geneName": "FGF10", "isVUS": "true", "variantName": "amplification"}, {"geneName": "JAK2", "isVUS": "true", "variantName": "I724T"}, {"geneName": "NOTCH2", "isVUS": "true", "variantName": "G1016S"}, {"geneName": "PARP1", "isVUS": "true", "variantName": "C908fs*9"}, {"geneName": "RICTOR", "isVUS": "true", "variantName": "amplification"}, {"geneName": "SDHA", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "Y447fs*172, K1819fs*63", "AlterationProperties": {"AlterationProperty": [{"dnaFraction": "14.99", "isEquivocal": "false", "name": "Y447fs*172"}, {"dnaFraction": "15.44", "isEquivocal": "false", "name": "K1819fs*63"}]}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2023) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). Several studies have reported no correlation between ARID1A loss and clinicopathological parameters in ovarian clear cell or endometrioid carcinomas or other endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907), whereas others suggest that ARID1A loss is a negative prognostic factor (Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352). There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited preclinical evidence from studies in ovarian cancer, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009), which are under investigation in clinical trials. Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in colorectal cancer cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05252390", "Include": "true"}, {"nctId": "NCT05053971", "Include": "true"}, {"nctId": "NCT04104776", "Include": "true"}, {"nctId": "NCT04657068", "Include": "true"}, {"nctId": "NCT04491942", "Include": "true"}, {"nctId": "NCT04514497", "Include": "true"}, {"nctId": "NCT05327010", "Include": "true"}, {"nctId": "NCT04840589", "Include": "true"}, {"nctId": "NCT05071937", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": {"Name": "Q546R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "2.13", "isEquivocal": "false", "name": "Q546R"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007, Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). PIK3CA mutation frequency is variable among different subtypes of ovarian cancer. Mutations were detected in 33% (32/97) of clear cell carcinomas and in 12% of advanced epithelial ovarian carcinomas; however, PIK3CA mutations were detected in 3% of high_grade serous ovarian cancers and in fewer than 1% of tumors in the TCGA ovarian serous cystadenocarcinoma dataset (Kuo et al., 2009; 19349352, Levine et al., 2005; 15837735, Matulonis et al., 2011; 21931712, Cancer Genome Atlas Research Network, 2011; 21720365). A study of ovarian clear cell carcinomas reported an association of coexistent alterations in ARID1A and PIK3CA with poor prognosis (Uehara et al., 2015; 26043110). There are differing reports on the impact of PIK3CA alteration on prognosis in patients with ovarian carcinoma; PIK3CA mutation or overexpression was associated with favorable survival in patients with ovarian clear cell carcinoma (Rahman et al., 2012; 22705003, Abe et al., 2013; 22955107), whereas PIK3CA amplification has been associated with higher grade ovarian tumors (Carden et al., 2012; 22556379, Kolasa et al., 2009; 19029838, Nakayama et al., 2007; 17351921) and with shorter survival in patients with ovarian cancer in general (Kato et al., 2007; 17590872, Woenckhaus et al., 2007; 17377809, Niskakoski et al., 2013; 23716351, Huang et al., 2011; 21563232). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038, Canaud et al., 2021; ESMO Abstract LBA23, Delestre et al., 2021; 34613809, Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108, Santin et al., 2020; 31934607, Damodaran et al., 2022; 35133871), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Varnier et al., 2019; 31351267, Basse et al., 2018; 32914004, Sultova et al., 2021; 33277683, Mackay et al., 2014; 24166148, Myers et al., 2016; 27016228, Dhami et al., 2018; 29588307, Harris et al., 2019; 30863722, Hanna et al., 2018; 29301825). The Phase 2 NCI_MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate (Damodaran et al., 2022; 35133871). However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)(Santin et al., 2020; 31934607). Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA_mutated solid tumors with or without PTEN alterations (Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108). In the Phase 2 MATCH trial for patients with PIK3CA_mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA_mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12) (Pascual et al., 2021; 32958578). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib is approved as a single agent for the treatment of patients with PIK3CA_related overgrowth spectrum (PROS) (Canaud et al., 2021; ESMO Abstract LBA23), but has shown limited activity as monotherapy for PIK3CA_mutated solid tumors with a Phase 1a study reporting an ORR of 6.0% (8/134) and a DCR of 58% (78/134) (Juric et al., 2018; 29401002).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04931342", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04526470", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Homologous Recombination status", "Include": "true", "Alterations": {"Alteration": {"Name": "HRD Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "HRD Not Detected"}}, "Interpretation": null, "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Loss of Heterozygosity score", "Include": "true", "Alterations": {"Alteration": {"Name": "LOH_Low", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "LOH_Low"}}, "Interpretation": "The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele (Swisher et al., 2016; 27908594); focal LOH events accumulate as genomic \"scars\" as a result of incorrect DNA double_strand break repair when the homologous recombination pathway is deficient (HRD) (Abkevich et al., 2012; 23047548, Wang et al., 2012; 22912389, Watkins et al., 2014; 25093514, Vanderstichele et al., 2017; 28950147). HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1 (Vanderstichele et al., 2017; 28950147, Watkins et al., 2014; 25093514, Cancer Genome Atlas Research Network., 2011; 21720365, Venkitaraman, 2003; 12736286). This sample harbors a genomic LOH score below levels that have been associated with improved rates of clinical benefit from treatment with the PARP inhibitor rucaparib in patients with platinum_sensitive, BRCA1/2 wild_type ovarian, peritoneal, or Fallopian tube carcinoma (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). However, patients with lower genomic LOH have also responded to rucaparib, and this type of LOH score does not preclude benefit from PARP inhibitors (Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score \u2265 16% was identified in 24.2% of BRCA1/2 wild_type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score < 16% and were BRCA1/2 wild_type (Elvin et al., 2017; ASCO Abstract 5512). Among the histological subtypes, LOH score \u2265 16% or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild_type samples, the median LOH score was significantly higher in serous as compared with non_serous cases (Elvin et al., 2017; ASCO Abstract 5512). In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2_mutated cases than BRCA1/2 wild_type cases (22.2% vs. 9.8%) (Elvin et al., 2017; ASCO Abstract 5512), and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with increased genomic LOH (Wang et al., 2012; 22912389, Abkevich et al., 2012; 23047548). One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma (Marquard et al., 2015; 26015868). In patients with high_grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age (Pedersen et al., 2013; 23716468). On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum_sensitive, BRCA1/2 wild_type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score \u2265 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). In the maintenance setting in platinum_sensitive, BRCA1/2 wild_type patients, rucaparib was superior to placebo in both the LOH score \u2265 16% (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score < 16% (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts (Coleman et al., 2017; 28916367). Similar results have been reported for maintenance treatment with niraparib in ovarian cancer (Mirza et al., 2016; 27717299) when using a different measure of HRD that includes genomic LOH (Telli et al., 2016; 26957554, Timms et al., 2014; 25475740). Increased LOH has also been associated with improved sensitivity to platinum_containing chemotherapy regimens in patients with ovarian or breast cancer (Wang et al., 2012; 22912389, Telli et al., 2015; 25847929, Isakoff et al., 2015; 25847936).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been reported in 1.6_19.7% of ovarian cancer samples (Segev et al., 2015; 26775351, Plisiecka_Ha\u0142asa et al., 2008; 18507046), including 3.8% (1/26) of ovarian endometrioid adenocarcinomas (Huang et al., 2015; 25195947), and 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs) (Strickland et al., 2016; ASCO Abstract 5514). No association of MSI_H with stage or survival was found in patients with ovarian cancer (Segev et al., 2015; 26775351, Aysal et al., 2012; 22189970). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TET2", "Include": "true", "Alterations": {"Alteration": {"Name": "E1151*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "50.87", "isEquivocal": "false", "name": "E1151*"}}, "Interpretation": "TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Alterations such as seen here may disrupt TET2 function or expression (Iyer et al., 2009; 19411852, Ko et al., 2010; 21057493, Yang et al., 2013; 22391558, Hu et al., 2013; 24315485, Wang et al., 2015; 25601757). TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBio_Zehir et al., 2017; 28481359). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2023). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Ovarian clear cell carcinoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 1.7% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). In a study of high grade serous ovarian cancer, homologous recombination (HR)_deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR_proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival (Strickland et al., 2016; 26871470). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "NUV_868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRD4, PARP, AR", "Locations": "California, Arizona, Michigan, Texas, Tennessee, Maryland, Virginia, North Carolina", "NCTID": "NCT05252390", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Testing A New Anti_cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1/2", "Target": "BRD3, BRD4, BRD2, BRDT, HDAC", "Locations": "Oklahoma, Connecticut, Florida", "NCTID": "NCT05053971", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "A Study of CPI_0209 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "EZH2, TOP1", "Locations": "Washington, Salamanca (Spain), Michigan, Illinois, Ohio, Massachusetts, New Jersey, New York", "NCTID": "NCT04104776", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "London (United Kingdom), Colorado, Oklahoma, Texas, Pennsylvania, Tennessee, Florida", "NCTID": "NCT04657068", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "California, Wisconsin, Ohio, Pennsylvania, New York, Maryland", "NCTID": "NCT04491942", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "ATR, TOP1", "Locations": "Arizona, Minnesota, Oklahoma, Missouri, Pennsylvania, Connecticut, Florida", "NCTID": "NCT04514497", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Testing the Combination of the Anti_cancer Drugs ZEN003694 (ZEN_3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial", "StudyPhase": "PHASE 2", "Target": "PARP, BRD4, BRDT, BRD2, BRD3", "Locations": "Illinois, Texas, Georgia", "NCTID": "NCT05327010", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, CTLA_4, BRD4, BRDT, BRD2, BRD3", "Locations": "Ohio, Pennsylvania, New York, Maryland", "NCTID": "NCT04840589", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Y447fs*172, K1819fs*63", "Title": "ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer", "StudyPhase": "PHASE 2", "Target": "BRD4, BRDT, BRD2, BRD3, PARP", "Locations": "Pennsylvania", "NCTID": "NCT05071937", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "A Study Evaluating the Efficacy and Safety of Biomarker_Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors", "StudyPhase": "PHASE 2", "Target": "AKTs, MEK, ERBB2, PD_L1, VEGFA", "Locations": "Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Moskva (Russian Federation), Malvern (Australia), Ankara (Turkey), Istanbul (Turkey), Brno (Czechia), Dresden (Germany), Prague (Czechia), Muenchen (Germany)", "NCTID": "NCT04931342", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Alpelisib and Paclitaxel in PIK3CA_altered Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_alpha", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04526470", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "Q546R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "1", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "2", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "3", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "4", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "5", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "6", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "7", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "8", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "9", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "10", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "11", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "12", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "13", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "14", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "15", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "16", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "17", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "18", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "19", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "20", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "21", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "22", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "23", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "24", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "25", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "26", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "27", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "28", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "29", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "30", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "31", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "32", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "33", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "34", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "35", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "36", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "37", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "38", "ReferenceId": "32568634", "FullCitation": "Yap TA, et al. J Clin Oncol (2020) pmid: 32568634", "Include": "true"}, {"number": "39", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "40", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "41", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "42", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "43", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "44", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "45", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "46", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "47", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "48", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "49", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "50", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "51", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "52", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "53", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "54", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "55", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "56", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "57", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "58", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "59", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "60", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "61", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "62", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "63", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "64", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "65", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "66", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "67", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "68", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "69", "ReferenceId": "34779417", "FullCitation": "Jin N, et al. J Clin Invest (2021) pmid: 34779417", "Include": "true"}, {"number": "70", "ReferenceId": "19349352", "FullCitation": "Kuo KT, et al. Am. J. Pathol. (2009) pmid: 19349352", "Include": "true"}, {"number": "71", "ReferenceId": "15837735", "FullCitation": "Levine DA, et al. Clin. Cancer Res. (2005) pmid: 15837735", "Include": "true"}, {"number": "72", "ReferenceId": "21931712", "FullCitation": "Matulonis UA, et al. PLoS ONE (2011) pmid: 21931712", "Include": "true"}, {"number": "73", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "74", "ReferenceId": "26043110", "FullCitation": "Uehara Y, et al. PLoS ONE (2015) pmid: 26043110", "Include": "true"}, {"number": "75", "ReferenceId": "22705003", "FullCitation": "Rahman M, et al. Hum. Pathol. (2012) pmid: 22705003", "Include": "true"}, {"number": "76", "ReferenceId": "22955107", "FullCitation": "Abe A, et al. Hum. Pathol. (2013) pmid: 22955107", "Include": "true"}, {"number": "77", "ReferenceId": "22556379", "FullCitation": "Carden CP, et al. Mol. Cancer Ther. (2012) pmid: 22556379", "Include": "true"}, {"number": "78", "ReferenceId": "19029838", "FullCitation": "Kolasa IK, et al. Cancer Biol. Ther. (2009) pmid: 19029838", "Include": "true"}, {"number": "79", "ReferenceId": "17351921", "FullCitation": "Nakayama K, et al. Int. J. Cancer (2007) pmid: 17351921", "Include": "true"}, {"number": "80", "ReferenceId": "17590872", "FullCitation": "Kato S, et al. Int. J. Cancer (2007) pmid: 17590872", "Include": "true"}, {"number": "81", "ReferenceId": "17377809", "FullCitation": "Woenckhaus J, et al. Virchows Arch. (2007) pmid: 17377809", "Include": "true"}, {"number": "82", "ReferenceId": "23716351", "FullCitation": "Niskakoski A, et al. Int. J. Cancer (2013) pmid: 23716351", "Include": "true"}, {"number": "83", "ReferenceId": "21563232", "FullCitation": "Huang J, et al. Genes Chromosomes Cancer (2011) pmid: 21563232", "Include": "true"}, {"number": "84", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "85", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "86", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "87", "ReferenceId": "34613809", "FullCitation": "Delestre F, et al. Sci Transl Med (2021) pmid: 34613809", "Include": "true"}, {"number": "88", "ReferenceId": "31619463", "FullCitation": "Morschhauser F, et al. Mol Cancer Ther (2020) pmid: 31619463", "Include": "true"}, {"number": "89", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "90", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "91", "ReferenceId": "35133871", "FullCitation": "Damodaran S, et al. J Clin Oncol (2022) pmid: 35133871", "Include": "true"}, {"number": "92", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "93", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "94", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "95", "ReferenceId": "32914004", "FullCitation": "Basse C, et al. JCO Precis Oncol (2018) pmid: 32914004", "Include": "true"}, {"number": "96", "ReferenceId": "33277683", "FullCitation": "Sultova E, et al. Arch Gynecol Obstet (2021) pmid: 33277683", "Include": "true"}, {"number": "97", "ReferenceId": "24166148", "FullCitation": "Mackay HJ, et al. Cancer (2014) pmid: 24166148", "Include": "true"}, {"number": "98", "ReferenceId": "27016228", "FullCitation": "Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228", "Include": "true"}, {"number": "99", "ReferenceId": "29588307", "FullCitation": "Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307", "Include": "true"}, {"number": "100", "ReferenceId": "30863722", "FullCitation": "Harris EJ, et al. Front Oncol (2019) pmid: 30863722", "Include": "true"}, {"number": "101", "ReferenceId": "29301825", "FullCitation": "Hanna GJ, et al. Clin Cancer Res (2018) pmid: 29301825", "Include": "true"}, {"number": "102", "ReferenceId": "32958578", "FullCitation": "Pascual J, et al. Cancer Discov (2021) pmid: 32958578", "Include": "true"}, {"number": "103", "ReferenceId": "26787751", "FullCitation": "Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751", "Include": "true"}, {"number": "104", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "105", "ReferenceId": "23047548", "FullCitation": "Abkevich V, et al. Br. J. Cancer (2012) pmid: 23047548", "Include": "true"}, {"number": "106", "ReferenceId": "22912389", "FullCitation": "Wang ZC, et al. Clin. Cancer Res. (2012) pmid: 22912389", "Include": "true"}, {"number": "107", "ReferenceId": "25093514", "FullCitation": "Watkins JA, et al. Breast Cancer Res. (2014) pmid: 25093514", "Include": "true"}, {"number": "108", "ReferenceId": "28950147", "FullCitation": "Vanderstichele A, et al. Eur. J. Cancer (2017) pmid: 28950147", "Include": "true"}, {"number": "109", "ReferenceId": "12736286", "FullCitation": "N. Engl. J. Med. (2003) pmid: 12736286", "Include": "true"}, {"number": "110", "ReferenceId": "28916367", "FullCitation": "Coleman RL, et al. Lancet (2017) pmid: 28916367", "Include": "true"}, {"number": "111", "ReferenceId": "26015868", "FullCitation": "Marquard AM, et al. Biomark Res (2015) pmid: 26015868", "Include": "true"}, {"number": "112", "ReferenceId": "23716468", "FullCitation": "Pedersen BS, et al. Genes Chromosomes Cancer (2013) pmid: 23716468", "Include": "true"}, {"number": "113", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "114", "ReferenceId": "26957554", "FullCitation": "Telli ML, et al. Clin. Cancer Res. (2016) pmid: 26957554", "Include": "true"}, {"number": "115", "ReferenceId": "25475740", "FullCitation": "Timms KM, et al. Breast Cancer Res. (2014) pmid: 25475740", "Include": "true"}, {"number": "116", "ReferenceId": "25847929", "FullCitation": "Telli ML, et al. J. Clin. Oncol. (2015) pmid: 25847929", "Include": "true"}, {"number": "117", "ReferenceId": "25847936", "FullCitation": "Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936", "Include": "true"}, {"number": "118", "ReferenceId": "20639862", "FullCitation": "Ito S, et al. Nature (2010) pmid: 20639862", "Include": "true"}, {"number": "119", "ReferenceId": "21496894", "FullCitation": "Guo JU, et al. Cell (2011) pmid: 21496894", "Include": "true"}, {"number": "120", "ReferenceId": "19411852", "FullCitation": "Iyer LM, et al. Cell Cycle (2009) pmid: 19411852", "Include": "true"}, {"number": "121", "ReferenceId": "21057493", "FullCitation": "Ko M, et al. Nature (2010) pmid: 21057493", "Include": "true"}, {"number": "122", "ReferenceId": "22391558", "FullCitation": "Yang H, et al. Oncogene (2013) pmid: 22391558", "Include": "true"}, {"number": "123", "ReferenceId": "24315485", "FullCitation": "Hu L, et al. Cell (2013) pmid: 24315485", "Include": "true"}, {"number": "124", "ReferenceId": "25601757", "FullCitation": "Wang Y, et al. Mol. Cell (2015) pmid: 25601757", "Include": "true"}, {"number": "125", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "126", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "127", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "128", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "129", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "130", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "131", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "132", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "133", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "134", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "135", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "136", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "137", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "138", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "139", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "140", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "141", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "142", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "143", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "144", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "145", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "146", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "147", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "148", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "149", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "150", "ReferenceId": "26871470", "FullCitation": "Strickland KC, et al. Oncotarget (2016) pmid: 26871470", "Include": "true"}, {"number": "151", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "152", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "153", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "154", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "155", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "156", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "157", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "158", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "159", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "160", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "161", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "162", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "163", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "164", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "165", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "166", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "167", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "168", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "169", "ReferenceId": "26775351", "FullCitation": "Segev Y, et al. Eur. J. Gynaecol. Oncol. (2015) pmid: 26775351", "Include": "true"}, {"number": "170", "ReferenceId": "18507046", "FullCitation": "Plisiecka_Ha\u0142asa J, et al. Anticancer Res. () pmid: 18507046", "Include": "true"}, {"number": "171", "ReferenceId": "22189970", "FullCitation": "Aysal A, et al. Am. J. Surg. Pathol. (2012) pmid: 22189970", "Include": "true"}, {"number": "172", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "173", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "174", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "175", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_12 22:21:44", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "911x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "11.9%"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "OVARY", "disease_ontology": "Ovary clear cell carcinoma", "flowcell_analysis": "2000026872", "gender": "female", "pathology_diagnosis": "Ovarian Cancer C56", "percent_tumor_nuclei": "30", "pipeline_version": "v3.18.0", "purity_assessment": "35.4", "specimen": "ORD_1537951_01*US1470939.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1537951_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Ovary", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "933.15", "name": "SQ_US1470939.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.173", "cds_effect": "2722delT", "depth": "734", "equivocal": "false", "functional_effect": "frameshift", "gene": "PARP1", "percent_reads": "17.3", "position": "chr1:226551707", "protein_effect": "C908fs*9", "status": "unknown", "strand": "_", "transcript": "NM_001618", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.1499", "cds_effect": "1339_1340TA>C", "depth": "647", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "14.99", "position": "chr1:27056343", "protein_effect": "Y447fs*172", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4757", "cds_effect": "326G>A", "depth": "782", "equivocal": "false", "functional_effect": "missense", "gene": "CDKN2B", "percent_reads": "47.57", "position": "chr9:22006077", "protein_effect": "R109H", "status": "unknown", "strand": "_", "transcript": "NM_004936", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.1794", "cds_effect": "1934C>T", "depth": "613", "equivocal": "false", "functional_effect": "missense", "gene": "FANCA", "percent_reads": "17.94", "position": "chr16:89839759", "protein_effect": "S645F", "status": "unknown", "strand": "_", "transcript": "NM_000135", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4801", "cds_effect": "4001_4002insGCA", "depth": "477", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "ARID1A", "percent_reads": "48.01", "position": "chr1:27100205", "protein_effect": "Q1334_R1335insQ", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4717", "cds_effect": "2171T>C", "depth": "814", "equivocal": "false", "functional_effect": "missense", "gene": "JAK2", "percent_reads": "47.17", "position": "chr9:5080268", "protein_effect": "I724T", "status": "unknown", "strand": "+", "transcript": "NM_004972", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.5087", "cds_effect": "3451G>T", "depth": "920", "equivocal": "false", "functional_effect": "nonsense", "gene": "TET2", "percent_reads": "50.87", "position": "chr4:106158550", "protein_effect": "E1151*", "status": "likely", "strand": "+", "transcript": "NM_017628", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.0213", "cds_effect": "1637A>G", "depth": "1035", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "2.13", "position": "chr3:178936095", "protein_effect": "Q546R", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.1544", "cds_effect": "5454_5457delGAAG", "depth": "900", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "15.44", "position": "chr1:27105842", "protein_effect": "K1819fs*63", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4954", "cds_effect": "3046G>A", "depth": "969", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH2", "percent_reads": "49.54", "position": "chr1:120483315", "protein_effect": "G1016S", "status": "unknown", "strand": "_", "transcript": "NM_024408", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4886", "cds_effect": "2093T>C", "depth": "876", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "48.86", "position": "chr7:55238212", "protein_effect": "I698T", "status": "unknown", "strand": "+", "transcript": "NM_201284", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"allele_fraction": "0.4083", "cds_effect": "1879C>T", "depth": "1134", "equivocal": "false", "functional_effect": "missense", "gene": "DAXX", "percent_reads": "40.83", "position": "chr6:33287218", "protein_effect": "P627S", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "6", "equivocal": "true", "gene": "RICTOR", "number_of_exons": "39 of 39", "position": "chr5:38942378_39074519", "ratio": "1.89", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"copy_number": "6", "equivocal": "true", "gene": "SDHA", "number_of_exons": "15 of 15", "position": "chr5:218437_256556", "ratio": "1.77", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}, {"copy_number": "6", "equivocal": "true", "gene": "FGF10", "number_of_exons": "3 of 3", "position": "chr5:44305096_44388784", "ratio": "1.88", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1470939.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.62", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}